Extended Data Fig. 1: The graphical approach used to control the type I error at a two-sided level of 0.049a for the analyses of the dual primary endpoints progression-free survival and overall survival. | Nature Medicine

Extended Data Fig. 1: The graphical approach used to control the type I error at a two-sided level of 0.049a for the analyses of the dual primary endpoints progression-free survival and overall survival.

From: Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial

Extended Data Fig. 1

aThe stopping boundaries for interim (50% information) and final analyses were computed with Lan-DeMets approximation to the O’Brien-Fleming boundary.

Back to article page